Acquisition of FDA approved product
Ended Indefinite Delivery Contract Awarded Last action
- Contract number
- W911SR22D0009
- Awardee
-
Resilience Government Services, Inc. UEI GC2RFAZK8G64
- Awarding agency
-
ACC Aberdeen Proving Ground
Army Contracting Command, Department of Defense
- Task orders
- 3 $101,767,164 obligated
Award facts
- Opportunity
-
- W911SR22R0040 Solicitation number
- Combined order value
-
- $101,767,164 Current, with exercised options
- $121,876,811 Potential, with all options
- Last date to order 100% complete
- IDV ceiling 41% used
- $249,006,382.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- Funding agency
- Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Not Available for Competition · 1 offer Only One Source
- Pricing
- Cost Plus Fixed Fee
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
Award details come from SAM.gov/FPDS.
About this IDV
Resilience Government Services, Inc., doing business as Nanotherapeutics Inc., was awarded a single-award Indefinite Delivery Contract (IDC) valued at $249.0 million by the Joint Program Executive Office (PEO) for Chemical and Biological Defense on January 3, 2022, with an ultimate completion date of December 30, 2025. This defense acquisition vehicle is designated for the acquisition of FDA-approved products and specifically supports the advanced development of monoclonal antibody drug product G03-52-01 through regulatory approval for prophylaxis against botulinum toxin exposure (both post-exposure and pre-exposure applications). No small business set-aside was utilized for this contract award. The IDC establishes the overarching procurement framework through which the Department of the Army Acquisition Support Center issues task orders for development, clinical testing, manufacturing scale-up, and regulatory approval activities.
Three delivery orders have been issued under this IDC to date, collectively valued at approximately $121.9 million and structured as cost-plus-fixed-fee arrangements. The initial delivery order ($107.9 million, issued January 4, 2022, Frederick, Maryland) supports Phase 2 clinical development of the botulinum neurotoxin monoclonal antibody countermeasure. A second delivery order ($4.9 million, issued June 16, 2022, Alachua, Florida) encompasses drug substance process characterization and research and development activities. The third and most recent delivery order ($9.1 million, issued March 7, 2023, Alachua, Florida) advances the program through drug substance and drug product process validation, Phase 3 clinical development, and storage/stability testing toward FDA licensure of the G03-52-01 product. Collectively, these task orders represent an integrated development pathway for a critical medical countermeasure against a significant biological threat agent, leveraging Resilience's specialized capabilities in biomanufacturing, clinical trial execution, process development, and pharmaceutical regulatory affairs.
Task orders
| Task order | Ordering agency | Obligated | Awarded |
|---|---|---|---|
| Drug substance (DS) process validation, drug product (DP) process validation, clinical development phase 3, and… | ACC Aberdeen Proving Ground | $4,278,565 | |
| DS process characterization | ACC Aberdeen Proving Ground | $4,459,366 | |
| Clinical development phase 2 study | ACC Aberdeen Proving Ground | $93,029,233 |
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Default | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract W911SR22D0009?
W911SR22D0009 was awarded to Resilience Government Services, Inc. by ACC Aberdeen Proving Ground (Army Contracting Command) on January 3, 2022.
How much is contract W911SR22D0009 worth?
Orders under W911SR22D0009 have obligated $101,767,164. Their combined potential value, with all options, is $121,876,811. W911SR22D0009's own ceiling is $249,006,382.
How many orders have been placed under contract W911SR22D0009?
3 orders have been placed under W911SR22D0009, the latest on March 7, 2023.
Which agency awarded contract W911SR22D0009?
ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911SR22D0009, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).
Who can order from contract W911SR22D0009?
W911SR22D0009 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract W911SR22D0009 competed?
The extent of competition for W911SR22D0009 was not available for competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV